← FDA DRUG APPROVALS

FDA ANDA · ANDA202682

ATOMOXETINE

Sponsor: HETERO LABS LTD V

APPLICATION
ANDA202682
TYPE
ANDA
ORIGINAL APPROVAL
2021-03-11
LATEST ACTION
2023-05-08
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
Prescription

Products

ATOMOXETINE HYDROCHLORIDEPrescription
ATOMOXETINE HYDROCHLORIDE EQ 100MG BASE · CAPSULE · ORAL
ATOMOXETINE HYDROCHLORIDEPrescription
ATOMOXETINE HYDROCHLORIDE EQ 60MG BASE · CAPSULE · ORAL
ATOMOXETINE HYDROCHLORIDEPrescription
ATOMOXETINE HYDROCHLORIDE EQ 25MG BASE · CAPSULE · ORAL
ATOMOXETINE HYDROCHLORIDEPrescription
ATOMOXETINE HYDROCHLORIDE EQ 10MG BASE · CAPSULE · ORAL
ATOMOXETINE HYDROCHLORIDEPrescription
ATOMOXETINE HYDROCHLORIDE EQ 80MG BASE · CAPSULE · ORAL
ATOMOXETINE HYDROCHLORIDEPrescription
ATOMOXETINE HYDROCHLORIDE EQ 40MG BASE · CAPSULE · ORAL
ATOMOXETINE HYDROCHLORIDEPrescription
ATOMOXETINE HYDROCHLORIDE EQ 18MG BASE · CAPSULE · ORAL

Approval history

2023-05-08Labeling · Supplement 1 · standardAP
2021-03-11UNKNOWN · OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →